MedTrace Logo

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus

NCT03219801 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-07-18

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus.

Conditions

Interventions

BIOLOGICAL

mesenchymal stem cells

SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Baoyong Yan, Doctor · The First Hospital of Hebei Medical University

  • Qingchi Liu Liu, Doctor · The First Hospital of Hebei Medical University

  • Quanhai Li, Doctor · The First Hospital of Hebei Medical University

  • Xiaohui Jia, Doctor · The First Hospital of Hebei Medical University

  • Xianyun Wang, Doctor · The First Hospital of Hebei Medical University

  • Fan Zhang, Bachelor · The First Hospital of Hebei Medical University

  • Yang Shen, Master · The First Hospital of Hebei Medical University

  • Bing Ma, Master · The First Hospital of Hebei Medical University

  • Wanyi Yin, Master · The First Hospital of Hebei Medical University

  • Dan Zhao, Master · The First Hospital of Hebei Medical University

  • Bojian Sun, Master · The First Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2018-12-30
Completion
2019-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219801 on ClinicalTrials.gov